Beta Bionics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Beta Bionics, Inc. (BBNX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Operating Activities
Net Income-54.76-44.10-64.75
Depreciation & Amortization2.282.092.09
Stock Based Compensation6.385.666.10
Change in Working Capital-12.15-5.31-2.79
Change in Accounts Receivable-7.62-4.490.00
Change in Inventory-11.44-1.190.00
Change in Accounts Payable1.520.72-0.08
Change in Other Working Capital2.94-0.680.01
Other Operating Activities12.789.900.01
Net Cash from Operating Activities-48.27-32.45-60.21
Investing Activities
Capital Expenditures-3.40-0.40-0.77
Purchases of Investments-72.13-69.300.00
Sales/Maturities of Investments72.000.000.00
Other Investing Activities0.050.000.00
Net Cash from Investing Activities-3.48-69.69-0.77
Financing Activities
Common Stock Issued0.100.030.39
Other Financing Activities-4.150.0011.41
Net Cash from Financing Activities55.62101.0356.78
Summary
Net Change in Cash3.87-1.11-4.20
Cash at Beginning of Period26.6727.7831.97
Cash at End of Period30.5326.6727.78
Free Cash Flow-51.67-32.85-60.98